Pascal Brandys

Mr. Brandys is the co-founder, Chairman and CEO of Phylex BioSciences, a company developing a universal SARS coronavirus vaccine. Mr. Brandys has a 30-year extensive and global experience in the biotechnology industry and international finance. From 2013 to 2019 Pascal Brandys was the co-founder and CEO of CompuVax, a leader in computational engineering of vaccines. Previously Mr. Brandys was President and Managing Director of Biobank Technology Ventures LLC and also Chairman and CEO of Genset, a genomics company he co-founded in 1989 and grew to a market capitalization of over $1.5 billion before its acquisition by Merck-Serono in 2002. Mr. Brandys has held numerous corporate directorships in public and private companies, most notably NASDAQ listed Innogenetics NV, ILOG SA, and Ceres, Inc. Mr. Brandys was also a pioneer in biotechnology investments in Europe and Japan as CEO of Unihon Services in Tokyo and Partner of Eurocontinental Ventures in London during the eighties. Mr. Brandys is a graduate of the Ecole Polytechnique of Paris and holds an MS in Economic Systems from Stanford University. Mr. Brandys was also the founding President of France Biotech, the French biotechnology trade association and he received the Outstanding Service to Biotechnology Award from the European Life Sciences Partnering Foundation.